A Phase 3 interventional study of Fluticasone Propionate in Bilateral Nasal Polyposis, sponsored by Optinose US Inc.. Completed at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.
Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral nasal polyposis. Two co-primary endpoints will be used in the study: reduction of nasal congestion/obstruction symptoms at the end of Week 4 of the double-blind treatment phase measured by the 7 day average instantaneous AM diary symptom scores, and reduction in total polyp grade (sum of scores from both nasal cavities) over the 16 weeks of the double-blind treatment phase as determined by the Lildholdt scale score measured by nasoendoscopy.
This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study designed to assess the efficacy and safety of intranasal administration of 3 doses of OPN-375 (100, 200, and 400 µg bid) in subjects with bilateral nasal polyposis and nasal congestion.
This study consisted of 3 phases. After signing informed consent, subjects who met eligibility criteria at Visit 1 (screening) entered the study.
Optinose US Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women must
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks
Drug: Fluticasone Propionate
Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks
Drug: Fluticasone Propionate
Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks
Drug: Fluticasone Propionate
Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks
Drug: Fluticasone Propionate
Delivered via Optinose Exhalation Delivery System
Also known as: OPN-375
Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase
Time frame: Baseline, Week 4 of the double-blind treatment phase
Change in Total Polyp Grade
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline
Time frame: Baseline, Week 16 of the double-blind treatment phase
Congestion/Obstruction Scores (7-day Instantaneous Morning)
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
Time frame: Baseline, Week 16 of the double-blind treatment phase
Change in Rhinorrhea Score (7-day Instantaneous Morning)
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
Time frame: Baseline, Week 16 of the double-blind treatment phase
Facial Pain or Pressure Score (7-day Instantaneous Morning)
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
Time frame: Baseline, Week 16 of the double-blind treatment phase
Hyposmia Score (7-day Instantaneous Morning)
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
Time frame: Baseline, Week 16 of the double-blind treatment phase
Sinonasal Outcome Test 22 (SNOT-22) Total Score
SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be
Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
MOS Sleep-R Score
The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.
Time frame: Baseline, Week 16 of the double-blind treatment phase
Rhinosinusitis Disability Index (RSDI) Total Score
The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.
Time frame: Baseline, Week 16 of the double-blind treatment phase
SF-36v2 - Mental Component
The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.
Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
SF-36v2 - Physical Component
The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.
Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Patient Global Impression of Change (PGIC) Score
Subject responses to the question: "Since starting the study drug, how would you rate the change in your symptoms?" Percentage includes patients who scored either "very much improved," "much improved," or "minimally improved."
Time frame: Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Peak Nasal Inspiratory Flow (PNIF)
The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.
Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label treatment phase
Polyp Grade of 0 in at Least One Nostril
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the end of open-label treatment phase
Nasal Polyp Surgery Eligilbilty
A subject was considered eligible for surgical intervention if the following conditions were met: * Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months. * Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks. * Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks. * Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).
Time frame: Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase
| Milestone | Placebo | 100 μg OPN-375 | 200 μg OPN-375 | 400 μg EDS-FLU |
|---|---|---|---|---|
| Started | 82 | 81 | 80 | 80 |
| Completed | 70 | 75 | 71 | 76 |
| Not completed | 12 | 6 | 9 | 4 |
| Withdrew: Adverse event | 4 | 2 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 6 | 0 | 3 | 2 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 2 | 0 |
| Milestone | Placebo | 100 μg OPN-375 | 200 μg OPN-375 | 400 μg EDS-FLU |
|---|---|---|---|---|
| Started | 68 | 72 | 67 | 75 |
| Completed | 67 | 70 | 64 | 73 |
| Not completed | 1 | 2 | 3 | 2 |
| Withdrew: Adverse event | 0 | 2 | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 4 Visit of the double-blind treatment phase
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms | -0.26 ± 0.08 | -0.53 ± 0.08 | -0.56 ± 0.08 | -0.67 ± 0.08 |
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. A summary of the changes from baseline to Week 16 in total polyp grade. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate Reduction in total polyp grade (sum of scores from both nasal cavities) at Week 16 of double-blind treatment phase; Included patients with nasal polyps at baseline
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Change in Total Polyp Grade | -0.57 ± 0.14 | -1.04 ± 0.14 | -1.14 ± 0.14 | -1.14 ± 0.14 |
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
| units on a scale | Placebo | OPN-375 100 μg Twice Daily | OPN-375 200 μg Twice Daily | OPN-375 400 μg Twice Daily |
|---|---|---|---|---|
| Congestion/Obstruction Scores (7-day Instantaneous Morning) | -0.53 ± 0.11 | -0.93 ± 0.10 | -0.99 ± 0.10 | -1.07 ± 0.10 |
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Change in Rhinorrhea Score (7-day Instantaneous Morning) | -0.50 ± 0.10 | -0.80 ± 0.10 | -0.89 ± 0.10 | -0.92 ± 0.10 |
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Facial Pain or Pressure Score (7-day Instantaneous Morning) | -0.41 ± 0.11 | -0.65 ± 0.10 | -0.72 ± 0.10 | -0.68 ± 0.10 |
Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing. 0: None 1. Mild, symptoms clearly present, but minimal awareness, and easily tolerated 2. Moderate, definite awareness of symptoms that is bothersome but tolerable 3. Severe, symptoms that are hard to tolerate, cause interference with activities or daily living The change from baseline in instantaneous morning diary symptom scores averaged over 7 days prior to the Week 16 Visit of the double-blind treatment phase
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Hyposmia Score (7-day Instantaneous Morning) | -0.23 ± 0.12 | -0.45 ± 0.11 | -0.53 ± 0.11 | -0.60 ± 0.11 |
SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Change from baseline to Week 16 | -10.96 ± 2.07 | -18.32 ± 2.05 | -19.56 ± 2.04 | -19.80 ± 2.05 |
| Change from baseline to Week 24 (all pts on 400 μg | -20.78 ± 2.10 | -21.20 ± 2.07 | -23.28 ± 2.08 | -21.72 ± 2.07 |
The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| MOS Sleep-R Score | -8.53 ± 1.61 | -10.96 ± 1.59 | -14.24 ± 1.59 | -10.66 ± 1.55 |
The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Rhinosinusitis Disability Index (RSDI) Total Score | -10.71 ± 2.07 | -17.08 ± 1.99 | -16.44 ± 2.02 | -16.37 ± 1.94 |
The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Week 16 | 0.70 ± 0.87 | 3.19 ± 0.84 | 4.03 ± 0.85 | 1.83 ± 0.82 |
| Week 24 (all pts on 400 μg OPN-375 BID wks 17-24) | 4.44 ± 0.83 | 3.37 ± 0.80 | 5.82 ± 0.84 | 3.61 ± 0.78 |
The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.
| units on a scale | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Week 16 | 2.67 ± 0.76 | 4.12 ± 0.74 | 5.19 ± 0.74 | 3.58 ± 0.72 |
| Week 24 (all pts on 400 μg OPN-375 BID wks 17-24) | 6.97 ± 0.78 | 6.55 ± 0.75 | 7.18 ± 0.78 | 4.90 ± 0.73 |
Subject responses to the question: "Since starting the study drug, how would you rate the change in your symptoms?" Percentage includes patients who scored either "very much improved," "much improved," or "minimally improved."
| Participants | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Week 16 | 51 | 56 | 62 | 67 |
| Week 24 (all pts on 400 μg OPN-375 BID wks 17-24) | 59 | 62 | 62 | 66 |
The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.
| L/min | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID |
|---|---|---|---|---|
| Week 16 | 17.26 ± 6.15 | 36.57 ± 6.06 | 35.94 ± 6.08 | 35.43 ± 5.95 |
| Week 24 (all pts on 400 μg OPN-375 BID wks 17-24) | 34.92 ± 6.31 | 41.61 ± 6.21 | 44.70 ± 6.27 | 35.64 ± 6.09 |
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
| Participants | Placebo | OPN-375 100 μg Twice Daily | OPN-375 200 μg Twice Daily | OPN-375 400 μg Twice Daily |
|---|---|---|---|---|
| Week 16 | 9 | 19 | 12 | 14 |
| Week 24 (all pts on 400 μg OPN-375 BID wks 17-24) | 17 | 24 | 16 | 19 |
A subject was considered eligible for surgical intervention if the following conditions were met: * Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months. * Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks. * Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks. * Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).
| Participants | Placebo | 100 μg OPN-375 | 200 μg OPN-375 | 400 μg EDS-FLU |
|---|---|---|---|---|
| Week 16 | 27 | 17 | 21 | 19 |
| Week 24 (all pts on OPN-375 400 mcg BID wks 17-24) | 15 | 14 | 17 | 16 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Double-Blind Phase) | 0/82 (0%) | 0/82 (0%) | 42/82 (51.2%) |
| OPN-375 100 μg BID (Double-Blind Phase) | 0/81 (0%) | 1/81 (1.2%) | 40/81 (49.4%) |
| OPN-375 200 μg BID (Double-Blind Phase) | 0/80 (0%) | 0/80 (0%) | 45/80 (56.3%) |
| OPN-375 400 μg BID (Double-Blind Phase) | 0/79 (0%) | 1/79 (1.3%) | 50/79 (63.3%) |
| OPN-375 400 μg (Open-Label Phase) | 0/282 (0%) | 2/282 (0.7%) | 38/282 (13.5%) |
| Event | Placebo (Double-Blind Phase) | OPN-375 100 μg BID (Double-Blind Phase) | OPN-375 200 μg BID (Double-Blind Phase) | OPN-375 400 μg BID (Double-Blind Phase) | OPN-375 400 μg (Open-Label Phase) |
|---|---|---|---|---|---|
| MenorrhagiaReproductive system and breast disorders | 0/82 | 0/81 | 0/80 | 1/79 | 0/282 |
| Nasal PolypsRespiratory, thoracic and mediastinal disorders | 0/82 | 1/81 | 0/80 | 0/79 | 1/282 |
| PneumoniaInfections and infestations | 0/82 | 0/81 | 0/80 | 0/79 | 1/282 |
| Event | Placebo (Double-Blind Phase) | OPN-375 100 μg BID (Double-Blind Phase) | OPN-375 200 μg BID (Double-Blind Phase) | OPN-375 400 μg BID (Double-Blind Phase) | OPN-375 400 μg (Open-Label Phase) |
|---|---|---|---|---|---|
| Epistaxis (Found on Nasoendoscopy)Respiratory, thoracic and mediastinal disorders | 3/82 | 8/81 | 9/80 | 13/79 | 4/282 |
| Nasal Mucosal DisorderRespiratory, thoracic and mediastinal disorders | 5/82 | 11/81 | 6/80 | 6/79 | 1/282 |
| Acute SinusitisInfections and infestations | 4/82 | 5/81 | 6/80 | 8/79 | 3/282 |
| Epistaxis (Spontaneously Reported by Subject)Respiratory, thoracic and mediastinal disorders | 3/82 | 3/81 | 7/80 | 6/79 | 12/282 |
| Upper Respiratory Tract InfectionInfections and infestations | 7/82 | 1/81 | 4/80 | 5/79 | 2/282 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 4/82 | 3/81 | 2/80 | 6/79 | 1/282 |
| Nasal Septal UlcerationRespiratory, thoracic and mediastinal disorders | 1/82 | 5/81 | 5/80 | 4/79 | 5/282 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/82 | 0/81 | 1/80 | 3/79 | 1/282 |
| NasopharyngitisInfections and infestations | 4/82 | 3/81 | 2/80 | 4/79 | 3/282 |
| BronchitisInfections and infestations | 2/82 | 2/81 | 2/80 | 3/79 | 0/282 |
| Age, Continuous(years) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Mean | 45.3 ± 13.0 | 44.9 ± 12.7 | 46.4 ± 12.7 | 43.9 ± 12.6 | 45.1 ± 12.7 |
| Sex: Female, Male(Participants) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Female | 46 | 41 | 32 | 42 | 161 |
| Male | 36 | 40 | 48 | 38 | 162 |
| Race/Ethnicity, Customized(Participants) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| White | 68 | 74 | 72 | 69 | 283 |
| Black/African American | 8 | 3 | 6 | 9 | 26 |
| Asian | 5 | 2 | 2 | 0 | 9 |
| Other | 1 | 2 | 0 | 2 | 5 |
| Region of Enrollment(Participants) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Canada | 4 | 5 | 5 | 4 | 18 |
| Czechia | 14 | 15 | 14 | 13 | 56 |
| United Kingdom | 3 | 2 | 2 | 4 | 11 |
| Ukraine | 16 | 17 | 16 | 16 | 65 |
| United States | 36 | 36 | 35 | 36 | 143 |
| South Africa | 9 | 6 | 8 | 7 | 30 |
| Total Polyp Grading Score (sum of scores from both nasal cavities)(Units on a Scale) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Mean | 3.8 (2 to 6) | 3.6 (2 to 6) | 3.9 (2 to 6) | 3.7 (2 to 6) | 3.75 (2 to 6) |
| Use of intranasal corticosteroid (ICS) treatment for polyps in past 10 years(Participants) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Count of participants | 77 | 77 | 76 | 75 | 305 |
| Previous sinus surgery for polyp removal or sinus surgery(Participants) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Count of participants | 33 | 34 | 27 | 30 | 124 |
| Previous polyp removal surgery via polypectomy only(Participants) | Placebo | OPN-375 100 μg BID | OPN-375 200 μg BID | OPN-375 400 μg BID | Total |
|---|---|---|---|---|---|
| Count of participants | 33 | 27 | 33 | 27 | 120 |
11 further baseline measures are reported on the registry.
Ran from Nov 2013 to primary completion in Aug 2015, 20 months.
Results were first posted in Dec 2018, 3 years 3 months after primary completion. A results delay was requested in Jul 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Optinose US Inc.